



## **Sosei to Present at the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco**

**Tokyo, Japan – 8 January 2018:** Sosei Group Corporation ('Sosei'; TSE Mothers Index 4565), one of the world's leading GPCR medicine design and development companies, today announced that Peter Bains, Chief Executive Officer will present at the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 8, 2018.

The presentation will begin at 10:30 a.m. Pacific Time in the Elizabethan A/B room at the Westin St. Francis Hotel. The presentation slides will be made available to shareholders following completion of the event. To access, please visit <http://www.sosei.com/en/ir/>.

-Ends-

### **Contacts for Sosei Group Corporation**

Chris Cargill  
Head of Investor Relations and Corporate Communications  
+44-(0)7912-892-199  
ccargill@sosei.com

### **About Sosei Group Corporation**

Sosei Group Corporation is an international biopharmaceutical company originating from Japan that discovers and develops innovative biopharmaceuticals for the treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. By utilizing its GPCR structure-based drug design platform technology, Sosei has established a product pipeline with first/best in class potential. Through development and commercialization partnerships, Sosei has already delivered two bronchodilators for COPD which generate significant and stable revenue streams that enable further growth. Sosei partners include Novartis, Allergan, AstraZeneca, MedImmune, MorphoSys, Teva, and Pfizer and we are actively looking for new partnerships to enhance the development of our products and help us deliver them to patients worldwide.

For further information about Sosei, please visit <http://www.sosei.com/en/>.

### **Forward-looking statements**

*This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely*

*on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*